Skip to main content
. 2015 Nov;100(11):1469–1476. doi: 10.3324/haematol.2015.128025

Figure 3.

Figure 3.

Kaplan-Meir analysis of overall survival (OS) based on hematologic response to treatment (A) OS on an ITT basis by hematologic response: the median OS was 74.7 months in those achieving CR/VGPR and 52.5 months in those achieving a PR compared to 8.8 months in non-responders (log rank P<0.0001); (B) OS for patients at the 6-month landmark analysis based on hematologic response: the median OS was 74.7 months in those achieving CR/VGPR and 52.5 months in those achieving a PR compared to 19.4 months for non-responders (log rank P<0.0001); (C) OS by response for patients with cardiac involvement in the ITT cohort: the median OS was 55.6 months in those with CR/VGPR and 20.2 months in those with PR and 6.4 months in the non-responders (log rank P<0.0001); (D) OS by treatment regime: the median OS was not reached in the bortezomib group compared to 25.2 months and 38.9 in the melphalan and thalidomide groups, respectively (log rank P=0.062).